Announcements Trials
Browse Landscape

Status

Completed 330Recruiting 282Active not recruiting 223Terminated 140Unknown 110Withdrawn 88Not yet recruiting 55Suspended 6Enrolling by invitation 2Temporarily not available 1No longer available 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Dermatologic 1CNS 1

Conditions

Melanoma 1Glioma 1Glioblastoma 1

Interventions

Amifampridine 4fludarabine phosphate 3gallium 68 PSMA-11 2fludarabine 2carbon-11 acetate 2Whole-Body Irradiation 2Magnetic Resonance Spectroscopy 2Ga(III)-DOTATOC 2Cyclophosphamide 23-Iodobenzylguanidine 2venetoclax 1veliparib 1ulocuplumab 1trametinib 1selinexor 1ponatinib 1pembrolizumab 1pegfilgrastim 1omburtamab I-131 1nirogacestat 1neratinib 1navitoclax 1ganitumab 1gallium Ga 68 dotatate 1fluorodopa F 18 1elotuzumab 1carfilzomib 1asparaginase erwinia chrysanthemi recombinant 1aldesleukin 1Vorinostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
No longer available × OTHER × pembrolizumab × Clear all
NCT03311542 2018-01-10

Expanded Access for Pembrolizumab (MK-3475)

Center Trials & Treatment

No longer available
CNSDermatologic

Glioblastoma, Glioma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡